Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00815516 · ClinicalTrials.gov registry record · Phase 3
Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis
A Phase 3 study, sponsored by Astellas Pharma Global Development.
- Terminated
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT00815516 is a Phase 3 study that was terminated before completion, run by Astellas Pharma Global Development. The registered enrollment target is 30 participants.
The verdict
NCT00815516, a Phase 3 study, was terminated before completion, sponsored by Astellas Pharma Global Development.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
The study will evaluate how effective and how safe the drug micafungin is when compared to the drug amphotericin B deoxycholate in treating neonates and young infants with certain fungal infections.
Interventions
- DRUG micafungin
- DRUG amphotericin B deoxycholate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-02 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00815516
The ClinicalTrials.gov registry entry for NCT00815516 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which micafungin is the first listed.
NCT00815516 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00815516 about?
NCT00815516 is a clinical study titled "Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis". The study will evaluate how effective and how safe the drug micafungin is when compared to the drug amphotericin B deoxycholate in treating neonates and young infants with certain fungal infections.
What is the current status of trial NCT00815516?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2013-02. Estimated completion is 2014-12.
What interventions are being tested in trial NCT00815516?
The interventions under investigation include: micafungin (DRUG), amphotericin B deoxycholate (DRUG).
Who is sponsoring clinical trial NCT00815516?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.